This study will enroll children and young adults (1-39 years) with recurrent or progressive supratentorial malignant brain tumors will be eligible. The first 3 participants enrolled will be > 8 years – 39 years.  ...

This is a registry study of children with previously treated, newly diagnosed, and recurrent/progressive/refractory ATRT. The registry will collect detailed clinical, radiographic, pathologic, and molecular data from enrolled participants. These data will be analyzed to identify prognostic...

This study will enroll children and young adults (ages 1-39) with newly diagnosed or recurrent craniopharyngioma and planned for standard of care biopsy or resection....

This study will enroll children and young adults (age 12 months to 39 years of age) with relapsed medulloblastoma....

This is a Phase 2, multi-center, open label study of patient aged 6 months to 25 years with recurrent or progressive LGG with a known activating BRAF mutation. Patients will be treated with once weekly Day101 (an oral tablet or liquid suspension) for approximately 2 years, while undergoing routine...

This study will enroll children (ages 3-17), adolescents, and adults (ages ≥ 18) with recurrent or progressive malignant brain tumors. Participants with midline tumors (e.g., midline HGG, DIPG, and diffuse midline glioma) will not be included....

This study will include participants with diffuse midline gliomas at all stages of the disease and recurrent primary malignant CNS tumors. Participants will receive ONC206 as single agent or in combination with radiation therapy in three cohorts of patients: 1) newly diagnosed, 2) at completion...

This study will enroll children and young adults (2-39 years of age) with diffuse midline gliomas (DMGs; excluding Grade 2, H3K27M negative tumors) at different stages of their disease. Cohort 1: Will include participants with newly diagnosed DMGs. Cohort 2: Will include participants with...

Patients 1-25 years of age with a histologically confirmed diagnosis of low-grade gliomas (LGGs) (WHO grade I-II) that is progressive after prior treatment or high-grade gliomas. A combination of trametinib and everolimus will be administered in two dosing schedules (continuous and...

In this study, we will investigate  the safety and immunologic activity of RNA-LP vaccines in adult patients with newly diagnosed GBM (MGMT unmethylated in adults only) and pediatric patients with pHGG....

This study will include children and young adults > 6 months to <25 years of age with recurrent or progressive high-grade glioma (HGG) who are candidates for surgical tumor debulking. This is a single arm pilot trial to evaluate the immunological local and systemic changes following...

This study will enroll children and young adults (between the ages of 2 to 25 years old) with Diffuse Midline Gliomas (DMGs, HLA-A*0201 positive and H3.3K27M positive)....

Patients will receive BGB-290 twice daily, once in the morning and once in the evening. Temozolomide will be administered once daily. Dosing should occur in the morning together with the BGB-290 dose. Patients will be instructed to swallow the capsules whole, in rapid succession, with water....

Please note, this study has closed to accrual and is no longer accepting patients. This study will include children and young adults (3-39 years of age) with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG who will undergo tissue collection as part of standard of care.  Patients...

Please note, this study has closed to accrual and is no longer accepting patients. || This is an open-label, ascending dose, single arm phase I/II study of MTX110 delivered by CED in patients with DIPG following standard of care focal radiotherapy. We will start with a single dose drug...

Eligible patients will receive TAK-580 once weekly by mouth. One course is 28 days. Subsequent courses will immediately follow, with no break in the administration of the drug....

Patients with solid tumors will receive REGN2810 intravenously (IV) every 2 weeks. This phase of the study will confirm the pediatric dose of REGN2810 and will not include treatment with radiation. DIPG and HGG patients will receive REGN2810 via IV every 2 weeks in combination with radiotherapy and...

Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System. Subjects randomized to Arm 2 (~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m^2 at least...

Please note, this study has closed to accrual and is no longer accepting patients. || This is an open label trial to assess the safety and tolerability of the adult-tolerated dose of hyperpolarized pyruvate for metabolic imaging in children with brain tumors who do not require sedation for their MR...

Please note, this study has closed to accrual and is no longer accepting patients. || Patients with NF1 and PN(s) that are progressive (growing) or causing significant morbidity will take binimetinib by mouth twice a day. One course is 28 days. Subsequent courses will immediately follow, with no...

Please note, this study has closed to accrual and is no longer accepting patients. || This is an open label safety study with an accelerated dose escalation design and early efficacy, single agent, multi institution trial using CED of nal-IRI in children with DIPG following standard of care focal...

Please note, this study has closed to accrual and is no longer accepting patients. || Patients with newly diagnosed high grade glioma (including midline and excluding DIPG) who have undergone surgery as part of their standard of care and can provide the necessary tumor tissue for analysis will be...

Please note, this study has closed to accrual and is no longer accepting patients. || Eligible patients will undergo focal radiation therapy after initial diagnosis as part of their standard of care per institutional guidelines. Patients must begin radiation therapy within 4 weeks of diagnosis by...

This is a Phase I, open-label, multicenter study for children and young adults with locally recurrent or disseminated reccurent medulloblastoma or atypical teratoid rhabdoid tumors (ATRT). This study is testing the safety and oncolytic activity of the attenuated modified measles virus (MV-NIS),...

Please note, this study has closed to accrual and is no longer accepting patients. || Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) who undergo a biopsy as part of their standard of care will be eligible for this study. Part of the tissue will be sent to TGEN for detailed...

Please note, this study has closed to accrual and is no longer accepting patients. || Patients will receive vemurafenib once daily by mouth. One course is 28 days. Subsequent courses will immediately follow, with no break in the administration of the drug. Clinical assessment will be required...

Please note, this study has reached accrual and is no longer enrolling patients. || Patients will receive everolimus once daily by mouth. One course is 28 days. Subsequent courses will immediately follow, with no break in the administration of drug. Clinical assessment will be required every 2...